glp 1 cardiovascular disease Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology 🚨 GLP-1 medications do not
Description
In summary, tirzepatide achieved more pronounced HbA1c reductions with a lower incidence of hypoglycemia at week 52 compared to insulin glargine
less than 14% on semaglutide
Robert Kushner: Well, in the first stage, which is that weight gain stage, you're in positive energy balance and the only way you put weight on is you're taking in more calories than you burn off
Drugs can shrink waistlines
They received additional once-weekly tirzepatide (5 mg, 10 mg, 15 mg) or a placebo for 40 weeks, starting with an initial dose of 2.5 mg per week and increasing by 2.5 mg every 4 weeks
AUTHOR CONTRIBUTIONS B.J
